End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
500 INR | -1.55% |
|
+0.37% | -5.19% |
06-03 | Tarsons Products Limited Announces Change of Name of Whole-Time Directors | CI |
05-31 | Transcript : Tarsons Products Limited, Q4 2024 Earnings Call, May 31, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.28 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.19% | 321M | B- | ||
-11.68% | 11.22B | B+ | ||
-10.38% | 7.58B | B- | ||
+27.58% | 5.48B | C | ||
+1.44% | 5.38B | B | ||
-17.38% | 3.77B | C | ||
+8.12% | 2.6B | - | - | |
-64.90% | 2.35B | D+ | ||
-10.17% | 2.25B | B- | ||
+26.75% | 2.2B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TARSONS Stock
- Ratings Tarsons Products Limited